Table 4 Multivariate analyses for recurrence-free and overall survival in patients with clinical stage I NSCLC
RFS | OS | |||
|---|---|---|---|---|
Variables | HR (95% CI) | P value | HR (95% CI) | P value |
Age at operation, y | ||||
< 70 | 1 | |||
≥ 70 | – | – | 2.39 (1.09–5.24) | 0.029 |
Serum CEA, ng/ml | ||||
≤ 5 | 1 | 1 | ||
> 5 | 1.03 (0.98–1.05) | 0.061 | 1.74 (0.79–3.81) | 0.163 |
SUVmax of primary tumor | ||||
≤ 2.3 | 1 | 1 | ||
> 2.3 | 3.78 (1.61–8.72) | 0.002 | 3.43 (1.36–8.61) | 0.008 |
D-dimer, μg/ml | ||||
≤ 1.0 | 1 | 1 | ||
> 1.0 | 1.92 (1.33–2.91) | 0.041 | 2.24 (1.05–4.69) | 0.032 |
Pleural invasion | ||||
Absent | 1 | |||
Present | 1.05 (0.98–1.09) | 0.071 | – | – |
Pathological stage | ||||
Stage I | 1 | 1 | ||
Stage II/III | 4.01 (1.64–9.91) | 0.003 | 4.11 (1.65–9.98) | 0.003 |